

## CURRICULUM VITAE

### PERSONAL INFORMATION

Name: Professor Thomas Powles  
Mobile +447932048109  
E Mail thomas.powles1@nhs.net  
Date of birth: 10.04.71

### ACADEMIC QUALIFICATIONS

July 1995 MB BS (University of London) St Bartholomew's Hospital  
July 1998 MRCP (Royal College of Physicians, London)  
Oct 1999 NTN THN/012/055/N (London Postgraduate Deanery)  
Apr 2004 Pan Thames Oncology course (RCR)  
Sept 2006 CCST Medical Oncology.  
Feb 2006 MD (University of London).

### **Summary**

Thomas Powles is a Professor of urology cancer at the Barts Cancer Institute, Queen Mary University of London (2012 onwards) and the Director of Barts Cancer Centre (2017 onwards), which is one of the UKs largest Cancer Centres with over 4000 new cancer patients per year and a CRUK Major Cancer Centre. He trained as an Oncologist at Imperial College. His MD thesis from the University of London was on mechanisms of resistance to systemic therapy in urology cancer. He has an international reputation for research and education. He has broad experience in a wide range of key areas such as urology cancer, precision medicine, immune oncology. He has excellent leadership skills as deemed by the Quality Care Commission when his role of director of Barts Cancer Centre was assessed. He has a prominent reputation in cancer care, leading a number of key projects (leading 8 Nature/Nature Medicine publications) and trials (over 20 randomised trials). He leads international cancer guidelines, is editor in chief of Europe's leading cancer journal (Annals of Oncology) and has a H index of approximately 100. He has a significant presence on social media (top 10 influencer on twitter at ASCO/ESMO) and was one of Nature top 10 scientist of 2023. He has lead ESMO guidelines for 6 years in GU cancer and has been on the EAU guidelines committee for 10 years.

### PRESENT APPOINTMENT

#### **Academic:**

- Professor of Urology Oncology at Barts Cancer Institute, London (2014)
- Co-lead for the Biomedical Research Centre NCRN grant and the CRUK Experimental Cancer Centre grant (both >£5m) (2022).
- Chair of clinical research strategy and delivery group.

#### **Information transfer:**

- Editor in Chief for Annals of Oncology: impact factor 51 (2023)
- Chair IMCORE cancer centre network: a collaboration of the world's 20 leading immune oncology centres. The goal is to develop new treatments and biomarkers. The budget is \$100m (2019)
- ESMO Nomination committee (2020-22)
- Uromigos Podcast with 300,000 listens
- Twitter with 10.2K followers

**Clinical:**

- Director of Barts Cancer Centre. Barts Health is the largest hospital trust in the UK, with a catchment area of over 2 million people. Delivering 41,000 radiotherapy fractions delivered and 37,000 cancer treatments delivered per annum (2021).
- Renal Oncology lead for London Cancer. This collaboration brings together a population of over 5 million people (2013).
- Chair of clinical research strategy and delivery group.

**Led/co-led the EMA or FDA approval of the following agents:**

- Atezolizumab in 2<sup>nd</sup> line UC (FDA and EMA) Powles et al Lancet 2014
- Avelumab in UC (FDA and EMA) Powles et al NEJM 2020
- Axitinib and pembrolizumab in RCC (EMA and FDA) Rini....Powles NEJM 2017
- Durvalumab in UC (FDA) Powles et al JAMA Onc 2017
- Enfortumab vedotin in UC (EMA) Powles et al NEJM 2021
- Pembrolizumab adjuvant RCC (EMA,FDA) Choueiri.... Powles 2021

**Publications and grant income:**

- H index of 98
- Over 50 peer review pubmed publications per annum.
- A total of >500 peer review publications on pubmed.
- Eight 1<sup>st</sup> or last author publications in Nature/Nature Medicine
- Grant income of > £15 million over the last 5 years
- Five 1<sup>st</sup> or senior NEJM publications.

**Presentations**

- Presented academic data in oral presentations at all of the major cancer meetings over the last 3 years GU-ASCO: X2 IO ESMO: X1 EAU: X2 ASCO: X2 ESMO: X2.
- Plenary presentations at ASCO (2021) and ESMO (2023)

**Journal involvement**

- Editorial board of BMC medicine & Clinical Genitourinary Cancer (2013 -2020).
- Regular peer reviewer for Nature, Nature Medicine, NEJM, Lancet and JCO.
- Editor in Chief for Annal of Oncology: impact factor 51

**Guidelines and pivotal cancer meeting involvement involvement**

- ESMO Track lead for non-prostate GU cancer 2021
- ESMO Guidelines lead for GU cancer 2020-present
- ESMO Immuno-Oncology Congress Steering Committee Member 2017-2018
- EMUC organising committee for 5 years

**Other commitments and achievements**

- Trustee for Kidney Cancer UK.
- Supervised 8 PhDs or MDs.
- Top 10 twitter influencer at ASCO22, ESMO 20, 21 , 23 (Onc-alert data).

- Visiting professor MD Anderson Cancer Centre 2023
- Nature Journal 'Top 10' scientist 2023
- ASCO GU bladder cancer award 2017
- Plenary presentations at all of the major cancer meeting (ESMO, EAU, ASCO, GU ASCO).

#### **Chief investigator of ongoing randomised III studies**

1. TIP vs TICE (conventional vs high dose chemotherapy) in platinum refractory germ cell tumors.
2. NIAGRA: A randomised phase III of neoadjuvant durvalumab + chemotherapy in operable bladder cancer.
3. DISCUS: A RII of 3 vs 6 cycles of standard chemotherapy followed by maintenance avelumab.
4. EV 302: A randomised phase III of enfortumab vedotin+pembrolizumab vs chemotherapy in first line advanced refractory bladder cancer.
5. VOLGA: Neoadjuvant triplet therapy in cisplatin ineligible muscle invasive bladder cancer.
6. ImVIGOR 011: A randomised phase III of adjuvant atezolizumab in ctDNA positive patients

#### **Education and training:**

- Lead for the tumour site specific module of the MSC course (cancer therapeutics) at QMUL (2008-2018).
- Supervisor for Special Study Module (SSM) at QMUL (2007-2011).
- Co-author of a medical textbooks : PACES for the MRCP.
- Book Chapters (n=3 in GU cancer)
- Mentoring 6 GU oncologists (5 female).
- Active participant in the ESMO diversity program.

#### **Knowledge Transfer:**

- Regular appearances on television and radio (BBC, LBC, ITV).
- Four leading articles in Mail on Sunday 2020- present
- Educational programs of all the major meetings (ASCO, ESMO etc)
- Top 10 social media influencer (top European) at ASCO ESMO and ASCO GU (23-24) (onlive data).